Closure of Early-Stage gRED Research Division and Reduction of Senior Management

Genentech, Inc., a subsidiary of Roche Holding AG, has initiated a major restructuring of its Genentech Research and Early Development (gRED) organization, which is responsible for early-stage research and development. This action will result in the departure of three key executives, including Vishva Dixit, Vice President, who has led the Physiological Chemistry department for 29 years, Man-Wah Tan, Vice President of the Infectious Diseases department, and Todd McDevitt, Vice President of the Cell Therapy department. This clearly signals Genentech's shift away from its past broad-based research approach and towards focusing on disease areas with higher probabilities of success and proven commercial viability.

Discontinuation of Infectious Disease Research and Reallocation of Resources to Oncology and Immunology

The most notable changes include the official closure of the Infectious Diseases and Physiological Chemistry research departments, as well as cost control measures for early-stage research. Genentech has developed innovative infectious disease therapies, such as the influenza treatment Xofluza (baloxavir marboxil), but has recently determined that the return on investment for R&D in the infectious disease area has declined significantly. As a result, it is aggressively streamlining non-core early-stage research projects and reallocating its limited resources to the oncology and immunology fields, which offer much larger markets and the potential for higher margins.

Absorption of External Platforms and Streamlining of Cell Therapy Development

The departure of Todd McDevitt, Vice President of the Cell Therapy department, suggests a significant shift in the cell therapy development strategy from internal research to external collaborations and acquired assets. Roche completed the acquisition of Poseida Therapeutics, Inc., a cell therapy specialist, for up to $1.5 billion (USD) in early 2025, bringing in a wealth of innovative platform technologies. In particular, Poseida's allogeneic CAR-T therapy candidate, P-BCMA-ALLO1, targeting multiple myeloma, is in Phase 1/1b clinical trials (NCT04960579) and has been granted FDA RMAT and orphan drug designations based on its high TSCM (memory T stem cell) ratio, making it a promising candidate to replace internal, self-developed platforms.

Restructuring of the Bio-Talent Ecosystem and Securing Long-Term Growth Drivers

Genentech's large-scale workforce reduction and department closures, while potentially causing short-term organizational disruption, are expected to have a positive impact on the overall financial health of the Roche Group in the long term. The world-class professionals in the infectious disease and physiological chemistry fields who have been released are likely to be absorbed into smaller biotech companies or competitors, injecting new vitality into the broader bio-ecosystem. Ultimately, Genentech has adopted a shrewd survival strategy by focusing on high-value, late-stage clinical platforms, such as Poseida's piggyBac technology, rather than high-risk, early-stage basic science, thereby accelerating its commercialization speed.